

LABORATORY MEDICINE BULLETIN

Official Communication of Precision Diagnostics and Therapeutics Program (Laboratory Medicine)

Date: 2021-12-03

Changes in cancer biomarker testing for Breast, Endometrial, Prostate, Thyroid and Urinary Bladder cancers

Audience:	Internal and External Clients		
Issuing Division	: Molecular Diagnostics Laboratory and Anatomic Pathology		
Enquiry:	Dr. Weei-Yuarn Huang Dr. Kenneth Craddock Dr. Bojana Djordjevic Dr. Michelle Downes Dr. Fang-I Lu Dr. Tra Truong	(416) 480-6100 ext. 7894 (416) 480-6100 ext. 7751 (416) 480-6100 ext. 4014 (416) 480-6100 ext. 87597 (416) 480-4279 (416) 480-4011	weeiyuarn.huang@sunnybrook.ca kenneth.craddock@sunnybrook.ca bojana.djordjevic@sunnybrook.ca michelle.downes@sunnybrook.ca fangi.lu@sunnybrook.ca tra.truong@sunnybrook.ca

With the implementation of next generation sequencing (NGS) and available funding from CCO, available immediately, we are currently offering our biomarker testing on breast, endometrial, prostate, thyroid and urinary bladder cancers.

1. Breast cancer

- Newly diagnosed breast cancer ER, PR by IHC and HER2 by IHC/FISH
- Newly diagnosed ductal carcinoma in situ (DCIS) ER by IHC
- Advanced/metastatic breast cancer, by clinician request PIK3CA gene

2. Endometrial cancer

• Newly diagnosed carcinoma – MLH1, MSH2, MSH6, PMS2, p53 by IHC

ER and PR, by clinician request

- Serous endometrial carcinoma, by clinician request HER2 by IHC/FISH
- Newly diagnosed high-grade endometrial carcinoma POLE gene

3. Prostate cancer

• Newly diagnosed advanced*/metastatic tumours - ATM, BRCA1, BRCA2, PALM2 gene panel

– AR by IHC

4. Thyroid cancer

• All metastatic thyroid cancer, including sporadic medullary and radio-iodine refractory well differentiated tumour – BRAF, HRAS, KRAS, NRAS, NTRK1, NTRK2, NTRK3, PPARG, RET gene panel

5. Urinary bladder cancers

- Newly diagnosed advanced*/metastatic tumours FGFR2, FGFR3 gene panel
- * Advanced bladder cancers: All ≥ pT3 bladder cancers at surgery, all N+, pT2 in transurethral resections if patient not undergoing cystectomy
- * Advanced prostate cancers: All ≥ pT3 prostate cancers at surgery, all N+; Global Grade Group 3-5 on biopsy

Page 1 of 1

The information in this Bulletin is current as of the date indicated above. However, it may be superseded by subsequent communications. Please check to make sure you are reviewing the most recent communique."